Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.45 |
| ▸ | RNPEP | Q9H4A4 | 3/20 | 0.39 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.39 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5701294 | 0.87 | GABRR1 (0.56) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL17285499 | 0.87 | BLM (0.73) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL233225 | 0.87 | BLM (0.73) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL16330413 | 0.82 | BLM (0.65) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL7179523 | 0.82 | BLM (0.65) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL6249628 | 0.80 | BLM (0.86) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL276749 | 0.80 | BLM (0.86) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL29082 | 0.80 | BLM (0.64) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL6254815 | 0.80 | BLM (0.86) | BLMGABRR1CYP1A2LTA4HACE2 | |
| SCHEMBL9001608 | 0.79 | ACE2 (0.64) | BLMGABRR1CYP1A2LTA4HACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160058882-A1 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES | IMMUNOGEN, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20160058882-A1 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES | IMMUNOGEN, INC. | 2016-03-03 | — | — | US | disclosed |
| US-9090629-B2 | Cytotoxic agents comprising new ansamitocin derivatives | IMMUNOGEN, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-9090629-B2 | Cytotoxic agents comprising new ansamitocin derivatives | IMMUNOGEN, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20130323268-A1 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES | IMMUNOGEN, INC. (US) | 2013-12-05 | — | — | US | disclosed |
| EP-2635301-A1 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES | ImmunoGen, Inc. (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012061590-A1 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES | IMMUNOGEN, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130323268-A1 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES | MLNR, ANXA6, ANXA4 | BLM 804/4885GABRR1 3945/4885CYP1A2 4327/4885 |
| US-20160058882-A1 | CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES | MLNR, ANXA6, ANXA4 | BLM 804/4885GABRR1 3945/4885CYP1A2 4327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.